Clinical Trials Logo

Type 2 Diabetes Mellitus clinical trials

View clinical trials related to Type 2 Diabetes Mellitus.

Filter by:

NCT ID: NCT03840850 Completed - Clinical trials for Type 2 Diabetes Mellitus

Type 2 Diabetes: Risk Perceptions and Self-management Behaviour

Start date: September 15, 2017
Phase: N/A
Study type: Interventional

This pilot randomised controlled trial (RCT) aims to assess the feasibility of using a new type of risk communication intervention for people with Type 2 diabetes mellitus (T2DM) in primary care and to evaluate its potential impact on risk perceptions and self-management behaviour. The study comprises 40 participants with T2DM randomly allocated to usual care supported by the risk communication intervention or usual care only.

NCT ID: NCT03837405 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

(R33 Phase) Delish Study: Diabetes Education to Lower Insulin, Sugars, and Hunger

Delish R33
Start date: December 12, 2018
Phase: N/A
Study type: Interventional

We plan an R33 phase trial in which 120 persons with type 2 diabetes (T2DM) will be randomized (using a 1:1 ratio) to education alone (Ed) on following a carbohydrate restricted diet for T2DM, or this same education content with added mindful eating/Mindfulness-Based Intervention components (Ed+MBI).

NCT ID: NCT03829891 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus

Start date: August 3, 2018
Phase: N/A
Study type: Interventional

The investigators aimed to assess the efficacy and safety of Beinaglutide versus glargine , in individuals with type 2 diabetes who did not achieve adequate glycaemic control with oral antidiabetic drug.

NCT ID: NCT03818581 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes

Start date: March 15, 2019
Phase: Phase 4
Study type: Interventional

The investigators aim to determine the effect of suvorexant on subjective total sleep time (TST) in suboptimally controlled Type 2 diabetics with chronic insomnia in a randomized placebo-controlled trial for 3 months.

NCT ID: NCT03817099 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

Malaysia Diabetes Ramadan Nutrition Plan (My Dia-RNP®): A Feasibility Study

MyDia-RNP
Start date: March 1, 2019
Phase: N/A
Study type: Interventional

Ramadan fasting is an important event for Muslims. During Ramadan, all healthy Muslims are asked to abstain from food and drink throughout the day and eat only during daybreak (also know as Sahur in Malay/Arabic language) and after sunset (also know as Iftar in Malay/Arabic language). Patients with type 2 diabetes (T2DM) can be exempted from fasting but most of them do not perceive themselves as sick, and they continue to fast. With so many Muslims with diabetes choosing to fast, there is an immediate need for evidence-based nutrition practice guidelines. This study is conducted to determine the feasibility of implementing the Ramadan Nutrition Plan named My Dia-RNP that is also incorporating diabetes-specific nutrition formula on dietary adherence and acceptability in patients with type 2 diabetes mellitus. We hypothesized that My Dia-RNP is feasible to be practiced by patients with type 2 diabetes.

NCT ID: NCT03814434 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Surgical Treatment of Periimplantitis in Patients With Risk Factors

Start date: May 28, 2018
Phase: N/A
Study type: Interventional

This study evaluates clinical and radiographic parameters among riks factor groups in patients with periimplantitis. This study will also treat and evaluate the patients response before and after surgical treatment.

NCT ID: NCT03811470 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

China Diabetes Registry by Metabolic Management Center

CDR-MMC
Start date: May 31, 2017
Phase:
Study type: Observational [Patient Registry]

Epidemiologic studies have revealed a tremendous increase in the prevalence of diabetes and related mortality worldwide. In order to meet all the challenges in the treatment of metabolic diseases in China, the National Metabolic Management Center (MMC) was founded in 2016. The objective of the MMC is to launch a new metabolic disease management model based on the Internet health information platform. It allows the application and evaluation of diabetes treatment strategies at these centers. The proprietary electronic medical database in the MMC will help the dynamic big-data analysis in diabetes epidemiology, prevention, diagnosis, and treatment. It will also provide prospective data support including economic evaluation in management of chronic diseases for the Healthy China 2030 strategy. Objective 1. The purpose of the present study is to establish a multi-center nationwide prospective database of diabetes patients in MMCs, including clinical data, biological samples library so as to explore the epidemiology, genetics, new biomarkers, risk factors, and prognostic methods related to diabetes and its complications, as well as other metabolic diseases. 2. To collect cross-sectional data from patients seen and treated at each MMC centers so as to evaluate: the current status of care of patients with diabetes and its related complications, as well as other risk factors treatment strategies at these centers. Patients'costs and quality of life (QoL) will also be evaluated. 3. To collect the prospective data of patients treated at each MMC centers in order to evaluate the strategies for the achievement of treatment goals, changes in management, control of risk factors, incidence and progression of all-diabetes related clinical endpoints (including mortality), behavioral changes, psychological well being as well as costs and QoL.

NCT ID: NCT03805191 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients

FLAT
Start date: January 10, 2019
Phase:
Study type: Observational

This is a multicentre observational study to investigate the improvement in glucose fluctuation of sufficient acarbose therapy on type 2 diabetes patient with high blood glucose fluctuation

NCT ID: NCT03804905 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

STUDIIO-Diabetes Pilot: STUdy of Drug Insurance to Improve Outcomes of Diabetes

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

Canada is the only country with a universal health insurance system that does not provide coverage for prescription drugs to all residents. One-third of working-age Canadians have no insurance. Importantly, many of these uninsured patients already face other barriers to good health: low income, new immigrants, single mothers, etc. For these patients, taking prescription drugs - especially chronic disease treatments that may be required lifelong - can be difficult due to high costs. Patients skip doses, delay renewing prescriptions, or simply do not fill prescriptions recommended by their doctors, because they do not have insurance to cover the costs of prescriptions. Previous research by our team has suggested that the lack of a universal drug insurance program for working-age Canadians affects the health and well-being of low-income people with diabetes. The goal of our research is to determine the clinical and economic impact of providing drug coverage for uninsured type 2 diabetics.

NCT ID: NCT03802487 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects

Start date: January 14, 2019
Phase: Phase 1
Study type: Interventional

Primary Objective: To assess the absolute bioavailability of sotagliflozin via administration of an intravenous (IV) microdose of a 14C-sotagliflozin tracer on top of a single oral dose of unlabeled sotagliflozin without charcoal administration Secondary Objectives: - To assess the PK of sotagliflozin and its main metabolite sotagliflozin-3-O-glucuronide (M19) after a single oral dose of sotagliflozin and an IV microdose of a 14C-sotagliflozin tracer without charcoal administration - To assess the safety and tolerability of single doses of sotagliflozin when administered with and without charcoal